Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak.
Giovanna TraviFrancesco PeracchiMarco MerliNoemi Lo ReElisa MatarazzoLivia TartaglioneAlessandra BielliGiorgia CasalicchioFulvio CrippaChiara S VismaraMassimo PuotiPublished in: Antibiotics (Basel, Switzerland) (2024)
Variable outcomes have been reported with cefiderocol in infections due to carbapenem-resistant Acinetobacter baumannii (CRAB). Nonetheless, it may be the only option for metallo-beta-lactamase-producing strains. We describe an outbreak of NDM-CRAB infections treated with cefiderocol. Thirty-eight patients were colonized and/or infected. Thirteen patients developed a systemic infection. A clinical cure was achieved in 10 (83%) patients, one VAP and 9 BSIs, at day 7. In vitro, the activity of cefiderocol does not appear to match in vivo effectiveness using currently available commercial tests. Despite high clinical cures, overall mortality remains high in severely ill patients. Cefiderocol may be considered in this specific setting, though the implementation of susceptibility tests and infection control measures is mandatory.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acinetobacter baumannii
- randomized controlled trial
- peritoneal dialysis
- healthcare
- cardiovascular disease
- patient reported outcomes
- escherichia coli
- pseudomonas aeruginosa
- drug resistant
- multidrug resistant
- metabolic syndrome
- coronary artery disease
- risk factors